Americans for Pharma Reform

Americans for Pharma Reform Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from Americans for Pharma Reform, Nonprofit Organization, 7816 Rose Garden Lane, Springfield, VA.

06/23/2026

Pres. Trump is taking on Big Pharma and lowering prescription drug prices by enacting Most Favored Nation Pricing.

80% of Americans agree - It's time for Congress to get to work and CODIFY MOST FAVORED NATION PRICING!

Take a stand. Demand action.

Call Congress Right Now - 202-224-3121

06/21/2026

Depending on insurance coverage, patients pay $900 to $1,300 a month for certain medications — for people paying out of pocket, that easily exceeds $15,000 a year for a single drug. Five or six competing manufacturers would crash that price, sometimes dramatically. Every year that competition stays out is worth billions of dollars in additional revenue, which is exactly why companies invest so aggressively in protecting their market position. A drug with growing demand and no real alternative is what businesses call a cash cow, and companies do everything they can to keep it producing exactly that way.

The podcast Big Pharma doesn't want you listening to — bustbigpharmapodcast.com/Platforms

06/20/2026

Every pharmaceutical executive bringing a blockbuster drug to market knows the clock is running — eventually competitors show up, eventually generics enter, eventually prices fall. The strategy for stopping that clock doesn't require new science. It requires new patents on the injection pen, the dosage, the packaging, the manufacturing process — one patent, then another, then another, each covering a slightly different piece of a product that hasn't actually changed. Stack enough of them and you don't get more innovation. You get a legal maze any competitor has to navigate before bringing a cheaper version of the exact same drug to market.

The podcast Big Pharma doesn't want you listening to — bustbigpharmapodcast.com/Platforms

06/19/2026

Behind every Ozempic headline — the celebrity endorsements, the waitlists, the cultural moment — sits a number that gets almost no coverage. 154 patents surrounding a single molecule. Not 154 separate breakthroughs. One drug, surrounded afterward by 154 separate legal filings covering delivery devices, dosing, and manufacturing variations, each one another wall between patients paying thousands of dollars a year and any competitor who might eventually bring the price down. You don't need a law degree to know what that number actually represents.

The podcast Big Pharma doesn't want you listening to — bustbigpharmapodcast.com/Platforms

06/19/2026

Most Favored Nation pricing ties what Americans pay for certain drugs to the lowest price the same company already accepts in another developed country. The industry's response was the standard playbook — innovation will suffer, the market will be disrupted, research will collapse. Here's what those talking points require you to forget: drug companies are already selling these exact medications overseas, right now, at the lower prices MFN would require, and doing it profitably. The innovation collapse isn't a future risk. It's a scenario the industry's own current business practices have already disproven.

The podcast Big Pharma doesn't want you listening to — bustbigpharmapodcast.com/Platforms

06/19/2026

The patent system was built with an expiration date — temporary exclusivity, then competition, then falling prices. The pharmaceutical industry's business model runs on extending the exclusivity as far past that expiration as legally possible, because every additional year competition stays out is another year of revenue at full monopoly pricing. Keep competition out and prices stay high. Keep prices high and the money keeps rolling in. That's the entire strategy — patent thickets, pay-for-delay settlements, product reformulations, each one turning a legal mechanism designed to expire into a billion dollar shield. Americans pay the highest drug prices in the world for far longer than the patent system was ever supposed to allow.

The podcast Big Pharma doesn't want you listening to — bustbigpharmapodcast.com/Platforms

06/18/2026

Celebrities and influencers built a $100 billion annual pharmaceutical market for free — larger than the GDP of some countries, larger than the entire global market for many other drug categories. A handful of companies with the relevant patents watched it materialize in real time and controlled the entire space. The question that followed inside those boardrooms wasn't how to help more patients access a breakthrough treatment. It was how to keep competition out long enough to collect the maximum return on a market that someone else built for them at no cost. That question, and the strategies it produced, is what this episode examines.

The podcast Big Pharma doesn't want you listening to — bustbigpharmapodcast.com/Platforms

06/18/2026

The patent system made a two-part deal with the public. Inventors get a temporary window of protection long enough to profit from their breakthrough. Then the window closes, competition enters, prices fall, and patients finally catch a break. Both halves have to hold for the deal to work. The pharmaceutical industry accepted the protection half enthusiastically and spent decades and billions — through patent thickets, pay-for-delay settlements, and product reformulations — ensuring the competition half arrives as late as possible, if it arrives at all. The bargain still exists in the law books. The second half was quietly dismantled in practice.

The podcast Big Pharma doesn't want you listening to — bustbigpharmapodcast.com/Platforms

06/17/2026

Traditional political capital is transactional — senators trading votes for contributions, contributions for access, access for the protection of specific industry interests. The pharmaceutical industry has been the most sophisticated buyer of it in Washington for thirty years, spending $450 million a year on an infrastructure built specifically to purchase and maintain it.

What two Senate primary results in the same cycle have just demonstrated is something that infrastructure cannot purchase. Voters who have an issue, understand it specifically, and are acting on it independently of party direction. Corey Stevens calls it voters' political capital — and the distinction matters because one kind can be bought and one kind can't. The campaigns following the data in 2026 already know which kind is moving.

The podcast Big Pharma doesn't want you listening to — bustbigpharmapodcast.com/Platforms

06/14/2026

Every campaign has a triage moment — the point where a specific vulnerability is visible enough to address and still fixable enough to survive if the campaign responds to it directly. Bill Cassidy's pharmaceutical contributions and his blocked MFN vote were his. The campaign's fatal miscalculation, according to Corey Stevens, was treating pharmaceutical industry relationships as too normalized to actually move primary voters. Big Pharma is Big Pharma. You can't take it down. That assumption is what transformed the triage moment into the final result. Louisiana voted. The campaign felt it coming and never found a way back. Every senator currently in the same position just watched the same window open.

The podcast Big Pharma doesn't want you listening to — bustbigpharmapodcast.com/Platforms

Address

7816 Rose Garden Lane
Springfield, VA
22153

Website

Alerts

Be the first to know and let us send you an email when Americans for Pharma Reform posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Organization

Send a message to Americans for Pharma Reform:

Shortcuts

Share

Category